A novel AKT inhibitor, AZD5363, inhibits phosphorylation of AKT downstream molecules, and activates phosphorylation of mTOR and SMG-1 dependent on the liver cancer cell type

Due to frequent phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway dysregulation, AKT is typically accepted as a promising anticancer therapeutic target. mTOR, in particular, represents a suitable therapeutic target for hepatocellular carcinoma, whilst suppre...

Descripción completa

Detalles Bibliográficos
Autores principales: ZHANG, YUNCHENG, ZHENG, YUANWEN, FAHEEM, ALI, SUN, TIANTONG, LI, CHUNYOU, LI, ZHE, ZHAO, DIANTANG, WU, CHAO, LIU, JUN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774473/
https://www.ncbi.nlm.nih.gov/pubmed/26998062
http://dx.doi.org/10.3892/ol.2016.4111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774473/
https://www.ncbi.nlm.nih.gov/pubmed/26998062
http://dx.doi.org/10.3892/ol.2016.4111

Ejemplares similares